Baskent Universitesi Adana Dr. Turgut Noyan Uygulama ve Arastirma Merkezi

Adana 01250

0 studies enrolling now · 3 studies all time

What they study most

Obesity, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer, Type 2 Diabetes

Studies at this site

• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) — Completed
• A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity — Running, not enrolling
• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer — Stopped early